Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Recruiting
Bristol-Myers Squibb
Phase 2
2012-11-01
The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to
control uveal melanoma.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow
the body's immune system to work against tumor cells.
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Recruiting
National Cancer Institute (NCI)
Phase 2
2012-11-01
The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to
control uveal melanoma.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow
the body's immune system to work against tumor cells.
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Recruiting
M.D. Anderson Cancer Center
Phase 2
2012-11-01
The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to
control uveal melanoma.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow
the body's immune system to work against tumor cells.
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Active, not recruiting
Janssen, LP
Phase 1/Phase 2
2012-08-02
The purpose of this study is to determine the side effects of treatment of the combination of
nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Active, not recruiting
Bristol-Myers Squibb
Phase 1/Phase 2
2012-08-02
The purpose of this study is to determine the side effects of treatment of the combination of
nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
